- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Early Indication of Androgen Deprivation Resistance
Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the treatment of prostate cancer with androgen deprivation therapy (ADT) and note that additional research is necessary to help determine which patient populations are at highest risk for developing resistance following ADT.
Dr Klein explains that after a patient receives ADT, the only indicator that providers have for detecting resistance is disease progression. Unfortunately, he adds, each patient responds differently and the time to onset of resistance is variable.
For this reason, Dr Klein emphasizes the need for additional population-based clinical studies and research on the activation of signaling pathways. Being able to categorize patients, look at specific cell surface markers, and conduct additional next-generation sequencing can help providers appropriately manage their patients, he remarks.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
